IVERIC bio (ISEE) 10-Q2019 Q3 Quarterly report

Filed: 12 Nov 19, 6:32am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: absence, acuity, aimed, Alexion, Allegro, arbitrary, arm, asymptomatic, autofluorescence, Barbara, baseline, BCVA, belonging, beneath, BL, broaden, burdensome, Casebia, chance, characteristic, chart, chosen, CNV, color, comparison, confound, conservative, corrected, daily, dark, deviated, deviation, Diabetic, disc, discarded, discrepancy, dismissing, disproportionate, distance, dosage, double, Drs, eleven, equated, expert, FAF, fashion, feet, fellow, Fleming, focal, fovea, foveal, fraction, highest, HIV, Hochberg, invade, issuable, iteration, ITT, Journal, junctional, landscape, layer, lesion, licensee, licensor, lieu, linearly, living, LL, LLP, longitudinal, luminance, lump, masked, MedDRA, mg, missed, missing, mixture, mm, MRM, multifocal, NDA, neovascularization, nerve, numerical, omitted, optic, outer, outlicensing, outweigh, overlying, paragraph, parliamentary, pattern, plateau, plausibly, poor, potency, predominantly, prespecified, profound, proliferate, protocol, ratio, reestablish, regression, Retinopathy, Richardson, robust, root, sample, screening, SD, slightly, Snellen, Sq, Stealth, stratification, stratified, stricter, strictly, subpopulation, subtle, suspected, text, tipping, trail, transformation, trouble, uncover, unevaluable, uninterpretable, unmasked, unmitigated, unstudied, untreated, unveiled, view, visit, warranted, withdrew, worse, younger, zone

Removed: agreed, antibody, creditable, dispute, dosed, enabling, footnote, guide, monotherapy, revert, systemically, timepoint

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated ISEE transcripts

ISEE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of IVERIC bio, Inc. (the "Company") for the period ended September 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Glenn P. Sblendorio, Chief Executive Officer of the Company, hereby certifies, pursuant to Rule 13a-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: November 12, 2019	By:	/s/ Glenn P. Sblendorio
		Glenn P. Sblendorio Chief Executive Officer (Principal Executive Officer)